NEW YORK – Revolution Medicines on Saturday presented data on the preliminary activity of RMC-4630 in combination with cobimetinib (Genentech/Exelixis' Cotellic) in KRAS-mutated colorectal cancer, and said that it will study its SHP2 inhibitor in combination with a drug being advanced by AstraZeneca.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.